Clinical trial · Interventional
Integrated Actionable Aging Assessment for Cancer Patients Pilot
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Aging is the greatest risk factor for cancer incidence and mortality. Geriatric screening is recommended to help with treatment discussions, inform intensity of treatment, and identify supportive care needs. Despite a strong evidence base, geriatric assessments are not implemented routinely in oncologic clinics. Similarly, important information on social determinants of health, mental health, and health behaviors are inconsistently assessed, and almost never in an integrated fashion. In an effort to support clinicians delivering the recommended goal-concordant care, the investigators will integrate assessment of geriatric issues, health behaviors, mental health, and social determinants of health into an efficient, actionable contextual assessment system for older cancer patients called Integrated Aging Assessment for Action for Cancer Patients (IA3-CP). The investigators will use D\&I strategies including co-creation engagement approaches and form-function methods to develop workflow processes that feasibly integrate the IA3-CP into usual initial assessment with the oncology team. Our objective is to develop and conduct a randomized pilot of the IA3-CP system and hypothesize that our results will show it can be implemented consistently, acted on, improve quality of care, and enhance patient-provider interactions.
Conditions
Conditions (10)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Bladder Cancer | Malignant Bladder Neoplasm | CURATED_EXACT | 0.92 |
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
| Hodgkin Lymphoma | Hodgkin Lymphoma | ONTOLOGY_EXACT | 0.90 |
| Kidney Cancer | Malignant Kidney Neoplasm | CURATED_EXACT | 0.92 |
| Leukemia | Leukemia | ONTOLOGY_EXACT | 0.90 |
| Lymphoid Leukemia | Lymphoid Leukemia | ONTOLOGY_EXACT | 0.98 |
| Monocytic Leukemia | Acute Monocytic Leukemia | ALIAS | 0.90 |
| Multiple Myeloma | Multiple Myeloma | CURATED_EXACT |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Assessment tool IA3-CP without SDoH | Other | — | UNRESOLVED |
| Assessment tool IA3-CP with SDoH | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- type
- EXPERIMENTAL
- label
- IA3-CP with SDoH
- description
- Assess IA3-CP with SDoH and provide feedback (provider \& patient)
- interventionNames
- Other: Assessment tool IA3-CP with SDoH
- type
- EXPERIMENTAL
- label
- IA3-CP only
- description
- Assess IA3-CP only without added SDoH and provide feedback (provider \& patient)
- interventionNames
- Other: Assessment tool IA3-CP without SDoH
- type
- NO_INTERVENTION
- label
- Control - usual care
- description
- Usual care: Assess IA3-CP without providing the feedback report
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 65 Years
- Maximum age
- 111 Years
Show eligibility criteria text
Inclusion Criteria: * Age \> /= 65 * Patient must agree to participate in all study-related activities * English or Spanish speaking * Attending initial visit to oncology Exclusion criteria * age \< 65 * primary language other than English or Spanish
References
Publications (0)
Data not yet available